50
Participants
Start Date
May 16, 2025
Primary Completion Date
April 30, 2028
Study Completion Date
April 30, 2028
Nivolumab
Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
Cabozantinib
Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
NOT_YET_RECRUITING
Centre Georges François Leclerc, Dijon
NOT_YET_RECRUITING
Institut Universitaire Du Cancer Toulouse- Oncopole Claudius Regaud, Toulouse
NOT_YET_RECRUITING
CHU Tours - Hôpital Bretonneau, Tours
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest - Angers, Angers
NOT_YET_RECRUITING
Centre Léon Bérard, Lyon
NOT_YET_RECRUITING
Hôpital Tenon, Paris
RECRUITING
Gustave Roussy, Villejuif
Collaborators (1)
Ipsen
INDUSTRY
Gustave Roussy, Cancer Campus, Grand Paris
OTHER